KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Cash (2016 - 2025)

Regeneron Pharmaceuticals has reported Change in Cash over the past 17 years, most recently at $610.6 million for Q4 2025.

  • Quarterly results put Change in Cash at $610.6 million for Q4 2025, up 27.95% from a year ago — trailing twelve months through Dec 2025 was $634.7 million (up 355.1% YoY), and the annual figure for FY2025 was $634.7 million, up 355.1%.
  • Change in Cash for Q4 2025 was $610.6 million at Regeneron Pharmaceuticals, up from $497.5 million in the prior quarter.
  • Over the last five years, Change in Cash for REGN hit a ceiling of $1.4 billion in Q3 2021 and a floor of -$2.0 billion in Q2 2023.
  • Median Change in Cash over the past 5 years was $153.4 million (2022), compared with a mean of $45.8 million.
  • Biggest five-year swings in Change in Cash: tumbled 4106.28% in 2023 and later skyrocketed 571.88% in 2025.
  • Regeneron Pharmaceuticals' Change in Cash stood at -$546.8 million in 2021, then rose by 29.52% to -$385.4 million in 2022, then surged by 249.87% to $577.6 million in 2023, then fell by 17.38% to $477.2 million in 2024, then increased by 27.95% to $610.6 million in 2025.
  • The last three reported values for Change in Cash were $610.6 million (Q4 2025), $497.5 million (Q3 2025), and -$1.1 billion (Q2 2025) per Business Quant data.